Blogs and articles

China issues 2021 national reimbursement drugs list, three key trends…

23 December 2021
Posted in

China published its annual update to the national reimbursement drug list (NRDL) on 3rd December, which will be implemented from 1st January 2022. A total of seventy-four drugs entered the NRDL and eleven were removed. Sixty-seven (91%) of the drugs that were added are novel therapies reimbursed for the first time in China. Price negotiation with the…

Read More

Build Back Better could set new precedent for US drug pricing controls

3 December 2021
Posted in

The US administration is on the cusp of doing what many other administrations have attempted and failed to do – passing new federal legislation that would regulate drug prices in the US. The Build Back Better social spending bill recently passed in the House of Representatives includes unprecedented drug pricing controls for certain drugs covered…

Read More

10 steps for a successful market access strategy

20 September 2021
Posted in

Pharmaceutical product launches come with a number of challenges when launching a new drug into the market. Streamlining the launch sequence for an asset is greatly improved with strong data and data analytics, powered by AI. GPI’s Pulse™ 2.0 pricing and marketing access data analytics platform is designed with powerful near-time pharma data across 95+…

Read More

GPI Employee Spotlight – David Grove

31 August 2021
Posted in

At GPI, people are at the heart of our success and we want you get to know our staff better. This month, the spotlight shines on our Head of Global Operation, David Grove. Dave sat down with us to discuss the diverse nature of his role, the collaboration and variety of life at GPI and…

Read More

GPI horizon, the price forecasting methodology that is transforming market access strategy

27 August 2021
Posted in

GPI horizon, GPI’s price forecasting and optimisation methodology, helps pharma companies continuously and transparently assess value and price for their assets, creating efficiencies and improving the quality of strategic decision-making. By utilising GPI’s real-world, robust market access data, GPI’s horizon methodology begins with a detailed market landscape and value driver analysis to build an indication-specific…

Read More

“It’s Time For A Prescription Drug Pricing Revolution…”

6 August 2021
Posted in

“It’s Time for A Prescription Drug Pricing Revolution, the consistent aspect of drug pricing in the United States is that the breadth of its variations and fluctuations are inexplicable to the consumer. A recent report by the CTO of health plan group at NTT Data,”. Kumar Srinivas has outlined how the same drug ranges in…

Read More

GPI Employee Spotlight – Tom Wright

29 July 2021
Posted in

I love collaboratively thinking about creative ways to use the depth and breadth of data we hold. Getting into the heads of our users and finding new ways to answer their questions. It’s been great fun from conception to implementation.

Read More

GPI Employee Spotlight – Pramod Mali

3 July 2021
Posted in

At GPI, people are at the heart of our success and we want you get to know our staff better. This month, we focus on a member of our team in Mumbai, Pramod Mali. Pramod sat down with us to discuss his role as a GPI Lead Business Analyst, learning opportunities at GPI and diversifying…

Read More

GPI Horizon represents the major disruption happening in the consulting industry

27 May 2021
Posted in

A blog conducted by CBI Insights (Killing Strategy: the disruption of management consulting) highlights the disruption of management consulting and how companies are responding, aiming for the perfect consultant/client relationship. The blog describes how technological innovation has driven change in the management consulting industry, disrupting the traditional methods and forcing the consulting industry to change. The classic…

Read More

Early Pricing and Market Access Forecasting for Orphan Assets

20 May 2021
Posted in ,

Leveraging a Value-Driven Approach to Price Forecasting GPI’s Eva Barkhauskaite, Rachel Jao, Preeti Patel and Tom Brockbank look at early pricing and market access forecasting for orphan assets. The research takes an analytical approach to asset price forecasting, and price value optimisation, designed to empower pricing and market access strategy. Objectives Orphan products could contribute to 45% of…

Read More